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ABSTRACT 
The aim of this study was to investigate the epidemiological characteristics, antigenic 
profile, perceptions, attitudes and practices of individuals who have been systematically non-
compliant in mass drug administration (MDA) campaigns targeting lymphatic filariasis, in the 
municipality of Olinda, State of Pernambuco, Northeastern Brazil. A pretested questionnaire 
was used to obtain information on socioenvironmental demographics, perceptions of 
lymphatic filariasis and MDA, and reasons for systematic noncompliance with treatment. 
A rapid immunochromatographic test (ICT) was performed during the survey to screen for 
filariasis. It was found that the survey subjects knew about filariasis and MDA. Filariasis 
was identified as a disease (86.2%) and 74.4% associated it with the presence of swelling in 
the legs. About 80% knew about MDA, and the main source of information was healthcare 
workers (68.3%). For men the main reasons for systematic noncompliance with MDA were 
that “the individual had not received the medication” (p=0.03) and for women “the individual 
either feared experiencing adverse reactions”. According to the ICT, the prevalence of 
lymphatic filariasis was 2%. The most important causes of systematic noncompliance were 
not receiving the drug and fear of side-effects. For successful implementation of MDA 
programs, good planning, educational campaigns promoting the benefits of MDA, adoption 
of measures to minimize the impact of adverse effects and improvement of drug distribution 
logistics are needed.
KEYWORDS: Lymphatic filariasis. Control program. Mass drug administration. Systematic 
noncompliance.
INTRODUCTION
Lymphatic filariasis (LF) is an endemic neglected disease in tropical and 
subtropical countries. In view of the human suffering, social stigma and costs 
associated with LF morbidity, and in response to a specific resolution of the World 
Health Assembly, the Global Program to Eliminate Lymphatic Filariasis (GPELF) 
was launched by the World Health Organization (WHO) in 2000, with the objective 
of eliminating LF as a public health problem by 20201,2.
The main strategy of GPELF for halting filariasis transmission consists of 
reducing the level of infection among humans by means of mass drug administration 
(MDA) using annual single doses of antifilarial drugs over a period of 4 to 6 
years3-5. All individuals living in endemic areas, with or without filarial infection, 
need to be included in MDA4. Fifty-five of the 73 endemic countries have active 
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GPELFs. During the first 13 years (2000-2012) of GPELF, 
6.37 billion annual single dose anti-filarial drugs were 
made available annually, of which 4.45 billion doses were 
consumed by the target populations6. This success was due 
to the efforts of the donor community, health ministries, 
community volunteers, NGOs and research institutions7.
In Brazil, GPELF activities have already achieved two 
major goals: elimination of LF in Belém, in the State of 
Pará8; and interruption of transmission in Maceió, in the 
State of Alagoas9. Despite this progress, LF persists as a 
public health problem in municipalities of the Metropolitan 
Region of Recife (Olinda, Jaboatão dos Guararapes and 
Recife), in the State of Pernambuco10-13. The treatment 
regimen adopted in Brazil has consisted of MDA with a 
single dose of diethylcarbamazine15.
In Olinda, MDA was started in 2007. The following 
criteria for implementing MDA were established: 
1) local situation of transmissibility (> 1% prevalence 
of microfilaremia); and 2) socioenvironmental risk14. 
Accordingly, 14 neighborhoods were considered to be 
priority 1 (high/ medium environmental risk and detection 
of transmission) (Figure 1). MDA was started in the Alto 
do Sol Nascente district and it followed a strategy of door-
to-door supervised treatment16,17. 
One challenge within the MDA program has been to 
achieve and maintain high treatment coverage. Annual 
MDA carried out at adequate levels of coverage – estimated 
to be at least 65% of the total population in endemic areas 
– should ultimately make elimination possible2. When a 
large proportion of the population is not included or refuses 
to participate in MDA, a potential parasite reservoir is left 
untreated, thus allowing the maintenance of transmission18. 
People who are systematically noncompliant with MDA 
threaten the success of the program, especially in areas 
with high baseline infection rates19. Further research to 
identify individuals who have never participated in MDA is 
needed18. Knowing the individual, social, cultural and health 
factors that interfere with MDA coverage and influence 
systematic noncompliance is important for strengthening 
the program and increasing the treatment coverage. 
The present study investigated the epidemiological 
characteristics, awareness of lymphatic filariasis and MDA, 
reasons for systematic noncompliance with treatment and 
antigenic profile of the population living in the endemic 
area of interest that did not comply with MDA.
MATERIALS AND METHODS
The municipality of Olinda, Pernambuco, has a total 
territorial area of 41 km2 and a population of 377,779 
inhabitants. In this municipality, the Alto da Bondade 
district (8,718 inhabitants) and the Alto da Conquista district 
(8,104 inhabitants) were chosen because they had high 
prevalence of LF14, constituted MDA evaluation units and 
had universal Family Health Program coverage. In these 
two municipalities MDA was started in 200716 and achieved 
coverage > 86%17 (Table 1). 
The study group comprised individuals who had 
systematically been noncompliant of the rounds of 
MDA. A total of 136 individuals were identified through 
Figure 1 - Map of the priority areas for the elimination of filariasis.
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the MDA database of Olinda’s Health Department, of 
whom 114 (83.82%) answered the questionnaire. Among 
those who did not answer the questionnaire, 15 had 
changed their addresses, two had died and five refused 
to participate in the study. Among the 114 individuals 
who answered the questionnaire, 12 refused to undergo 
the rapid immunochromatographic test (ICT) for LF and 
were excluded from the study. Thus, a final total of 102 
individuals remained in the study.
Home visits were made, and these 102 individuals 
consented to participate in the project through signing 
an informed consent statement. They were then given 
a semi-structured questionnaire with questions on 
socioenvironmental demographics, LF, MDA and the 
reasons for systematic noncompliance with treatment. 
Following this, the ICT was applied to screen for 
filariasis20. The test was performed in accordance with 
the manufacturer’s instructions and the results were read 
by specialized technicians 10 minutes later. Among the 
individuals who tested positive in the antigen assay, 10 mL 
of venous blood was drawn between 11:00 pm and 01:00 am 
in order to detect microfilaria by means of the membrane 
filtration method21.
The data gathered were stored and analyzed using the 
Epi Info statistics package, version 7 (Centers for Disease 
Control and Prevention, Atlanta, GA, USA).
This study received prior approval from the institution’s 
Research Ethics Committee (CAAE 0015.0.095.000-11). 
LF-positive cases were treated in Olinda’s Health 
Department. 
RESULTS
The prevalence of systematic noncompliance was 
higher among women than among men (1.7:1). The mean 
age of the systematically noncompliant individuals was 49 
years (range: 7 to 99 years). Regarding marital status, the 
largest proportion of the individuals declared that they were 
married (42.2%). A lack of formal schooling was noted in 
16.7% of the population (Table 2).
All the homes visited were masonry constructions, of 
which 86.3% had an external wall coating; 8.8% of the 
homes consisted of one room. Sewage disposal from 86 
(84.3%) of these homes was into a rudimentary cesspit. 
It should be noted that in the cases of 14 homes (13.7%), 
Table 1 - Coverage with annual single-dose DEC in Alto da Bondade and Alto da Conquista, Olinda, Brazil
Ano
Alto da Bondade Alto da Conquista
No. of eligible 
participants MDA Noncompliance
Coverage 
(%)
No. of eligible 
participants MDA Noncompliance
Coverage 
(%)
2007 6.243 1.020 86 7.465 639 92
2008 6.200 606 91 7.228 370 95
2009 6.108 506 92 8.027 533 94
2010 6.097 684 90 7.834 602 93
2011 5.336 318 94 5.238 318 94
2012 4.558 739 86 4.105 167 96
2013 3.674 1.662 69 5.060 220 96
Table 2 - Demographic characterization of the systematic 
noncompliance population with mass drug administration, 
Olinda, Brazil
Demographic variables n (%)
Gender 
Female 65 (63.7)
Male 37 (36.3)
Age (years) 
7 – 14 8 (7.8)
15 – 24 11 (10.8)
25 – 64 53 (52.0)
65 – 99 30 (29.4)
Marital status
Married 43 (42.2)
Single 30 (29.4)
Widowed 19 (18.6)
Separated 10 (9.8)
Educational level 
Illiterate 17 (16.7)
Incomplete primary education (years 1-5) 33 (32.4)
Complete primary education (years 1-5) 16 (15.7)
Incomplete primary education (years 6-9) 11 (10.8)
Complete primary education (years 6-9) 2 (1.9)
Incomplete secondary education 5 (4.9)
Complete secondary education 18 (17.6)
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sewage was discharged directly into ditches. The most 
prevalent form of water supply in the homes was from 
the general water supply network. Regarding solid waste 
disposal, 93 (91.2%) of the interviewees declared that their 
garbage was collected by the municipal public services. 
Regarding monthly family income, 33.3% earned up to one 
minimum wage (Table 3). 
Approximately 90% of the interviewees identified 
LF as a disease, the majority being women (p>0.05), and 
74.4% reported that a swollen leg was the main symptom. 
Approximately 20% “claimed that LF is transmitted by 
mosquitoes”, and most women “answered that the disease 
can be cured” (p<0.05). Treatment with diethylcarbamazine 
was cited by 62.9% of the 70 individuals who claimed that 
LF can be cured (Table 4).
Table 4 shows that awareness of MDA was reported by 
80.4% of the interviewees, being 69.5% women, “who said 
that family healthcare professionals were their main source 
of information. MDA was perceived to be a drug that is 
distributed by family healthcare professionals” (39%). The 
women also considered that “MDA was a positive benefit for 
the population” (p< 0.05) and “believed that the medication 
caused adverse reactions” (p< 0.05) 
For men the main reasons for systematic noncompliance 
with MDA were that “the individual had not received the 
medication” (p< 0.05) and for women “the individual 
either feared experiencing adverse reactions to 
diethylcarbamazine” (p< 0.05), and for both sexes “the 
individual had not taken the drug because he did not have 
the disease” (Table 4).
Among the population studied, two cases (one male 
and one female, aged 13 and 39 years, respectively) 
tested positive for LF antigens. These cases did not show 
microfilaremia in the night membrane filtration method. 
DISCUSSION
The population that was systematically noncompliant 
with MDA in the area analyzed was mainly composed 
of married women with low educational levels. Previous 
studies have shown that females frequently present lower 
rates of compliance with MDA. The reasons cited have 
included pregnancy, lactation and fear of spontaneous 
abortion, along with domestic situations in which women 
are prohibited from participating in MDA because of their 
husbands’ negative beliefs about it22. This finding indicates 
that there is a need for a differentiated approach towards 
the female population in order to achieve more effective 
treatment coverage. 
LF is considered to be one of the main neglected diseases 
and is predominantly distributed in areas with poor social 
conditions and deficient sanitary infrastructure23. The 
results from the present study indicate that, for more than 
90% of the population studied, water was supplied and 
solid waste was collected by public services. However, 
the sewage disposal system exhibited favorable conditions 
for Culex quinquefasciatus to breed24. For approximately 
85% of the homes, sewage disposal consisted of discharge 
into rudimentary cesspits, while for 13.7% this was done 
into open ditches. Studies conducted in the Metropolitan 
Region of Recife have correlated the endemicity of LF 
with the population’s social and environmental conditions. 
Poor environmental conditions were associated with family 
income ≤ 268 USD/month in 30% of the cases. Areas with 
worse socioenvironmental conditions were at higher risk 
of exhibiting this parasitosis14,25. 
The main tool for eliminating LF in endemic areas is 
MDA. However, its application is not satisfactory in all 
endemic countries, given that low compliance with treatment 
Table 3 - Socioenvironmental characterization of the systematic 
noncompliance population with mass drug administration, 
Olinda, Brazil
Socioenvironmental variables n (%)
Construction material of the internal walls of the home
Masonry with coating 88 (86.3)
Masonry without coating 14 (13.7)
Number of rooms in the home 
1 9 (8.8)
4 to 6 56 (54.9)
7 or more 37 (36.3)
Sewage disposal system in the home
Rudimentary cesspits 86 (84.3)
Ditch 14 (13.7)
Other 2 (2.0)
Water supply system in the home
General water supply network 93 (91.3)
Well on the property 3 (2.9)
Well outside the property 3 (2.9)
Other 3 (2.9)
Domestic waste disposal
Collection by public services 93 (91.2)
Burning 7 (6.9)
Disposed of in ditches or fields 2 (1.9)
Family income/month (minimum wage= BRL 268) 
None 2 (1.9)
Up to 1 minimum wage 32 (31.4)
From 1 to 4 minimum wages 68 (66.7)
Rev Inst Med Trop São Paulo. 2017;59:e23
Knowledge, attitudes and perceptions regarding lymphatic filariasis
Page 5 of 9
Table 4 - Knowledge of lymphatic filariasis and MDA, and reasons for systematic noncompliance according to sex in Alto da 
Bondade and Alto da Conquista, Olinda, State of Pernambuco, Brazil
Lymphatic filariasis-related variables n (%) Female (%) Male (%)
What is Filariasis?
It is a disease that leads to swelling of the leg* 53 (51.9) 41 (77.4) 12 (22.6)
It is a disease that leads to swelling of the leg and is transmitted by the muriçoca (mosquito) 16 (15.7) 09 (56.3) 07 (43.7)
It is a disease transmitted by the muriçoca (mosquito) 08 (7.8) 03 (37.5) 05 (62.5)
It is a disease that leads to swelling of the leg and testicles 07 (6.8) 03 (42.9) 04 (57.1)
It is a disease 04 (3.9) 01 (25) 03 (75)
Other (It is a disease that causes redness of the leg; Blood worm) 05 (5.0) 02 (40) 03 (60)
Does not know how to describe it 04 (3.9) 03 (75) 01 (25)
Did not respond 05 (5.0) 03 (60) 02 (40)
Can Filariasis be treated? 
Yes* 70 (68.6) 44 (62.9) 26 (37.1)
Can be cured if treated early 21 (30.0) -- --
If the prescribed medication is taken correctly 19 (27.2) -- --
Medication plus test 04 (5.7) -- --
Does not know or did not respond 26 (37.1) -- --
Does not know* 16 (15.7) 11 (68.75) 05 (31.25)
MDA treatment-related variables 
Have you heard of Mass Treatment?* 
Yes* 82 (80.4) 57 (69.5) 25 (30.5)
No 20 (19.6) 08 (40) 12 (60)
Source of information on Mass Treatment?    
Community health agent or other health professional 56 (68.3) 39 (47.6) 17 (20.7)
Family member/friend/neighbor 11 (13.4) 8 (9.8) 3 (3.7)
Media 06 (7.3) 4 (4.9) 2 (2.4)
Flyer/advertising materials 01 (1,2) 0 1 (1.2)
Other 02 (2.4) 2 (2.4) -
Does not know 06 (7.3) 4 (4.9) 2 (2.4)
How is Mass Treatment performed?
Mentions how the medication is distributed and/or dosage* 32 (39.0) 23 (71.9) 09 (28.1)
Mentions that it is necessary to take the medication* 20 (24.4) 15 (75) 05 (25)
Does not know 16 (19.5) 08 (50) 08 (50)
Confuses the treatment with the test 04 (4.9) 03 (75)  01 (25)
Ignored 05 (6.1) 03 (60) 02 (20)
Other (Use of repellents) 05 (6.1)  05 (100) -
Opinion on Mass Treatment
Considers it beneficial to the population* 70 (85.3) 48 (68.6) 22 (31.4)
Does not know 06 (7.3) 04 (66.7) 02 (33.3)
Criticizes the follow-up 03 (3.7) 03 (100) -
Other 03 (3.7) 02 (66.7) 01 (33.3)
Reasons for treatment noncompliance -related variables 
The medication causes adverse reaction
Yes* 51 (62.2) 36 (70.6) 15 (29.4)
No 16 (19.5) 09 (56.2) 07 (43.8)
Does not know 15 (18.3) 12 (80) 03 (20)
Reason for noncompliance with MDA*
Did not receive the medication/the health professional failed to deliver it* 21 (20.6) 07 (33.3) 14 (66.7)
Fear of experiencing adverse reactions* 26 (25.4) 20 (76.9) 06 (23.1)
Did not accept treatment because does not have the disease 12 (11.8) 06 (50) 06 (50)
Has a preexisting condition* 10 (9.8) 10 (100) -
Believes there are restrictions due to age 05 (4.9) 03 (60) 02 (40)
Does not like to take drugs 03 (2.9) 02 (66.7) 01 (33.3)
Would only take it if prescribed 02 (2.0) 02 (100) -
Other (Fear to die; The medicine is not suitable for all cases of the disease; The 
medication is not suitable for children)
18 (17.7) 11 (66.1) 07 (39.9)
Did not respond 05 (4.9) 03 (60) 02 (40)
*p < 0,05
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is a serious obstacle26. There is no doubt that the success of 
LF elimination programs depends largely on their capacity 
for reaching and maintaining high levels of compliance with 
MDA27. In this regard, surveys on awareness, attitudes and 
practices are considered to be essential for sensitizing the 
population regarding disease and the importance of MDA28. 
In Brazil, the present study was the first to investigate 
systematic noncompliance with MDA. 
In this study, almost all the individuals studied 
recognized LF as a disease and were able to describe a 
symptom. However, despite their knowledge of LF, this 
did not seem to affect their low compliance with MDA. 
Studies conducted on populations in endemic areas in 
India29, Tanzania30 and Malaysia31 revealed that there were 
individuals with little or no awareness of LF, even though 
the areas were considered endemic. 
In the present study, more than half of the interviewees 
associated LF with its chronic forms (i.e. “swelling of the 
leg”, “swelling of the testicles” and “swelling of the leg 
and testicles”). In endemic areas, popular awareness of 
the disease is common, especially with regard to chronic 
clinical LF. However, most people are unaware of the role of 
mosquitoes in transmission of this parasitosis32. In Olinda, 
Brazil, less than one-fourth of the interviewees were aware 
of the role of C. quinquefasciatus in LF transmission. 
For control or elimination strategies regarding a given 
disease to be successful, the population involved firstly needs 
to be aware of the disease. In the municipality of Olinda, 
MDA is performed by family healthcare professionals. 
Most of the interviewees were aware of MDA, and the 
major sources of information were community health agents 
or other healthcare professionals. In a study in India, the 
people who administered the drug were the most important 
people in MDA programs, and their attitude determined 
whether compliance would be low. Thus, training and 
capacity building are essential for increasing compliance 
with MDA33. Effective drug delivery strategies and repeated 
home visits are needed in order to improve coverage34. 
Furthermore, the media (television, radio and flyers 
and other advertising materials) are also relevant means 
of communication regarding MDA. Visual and oral media 
are strategic tools for communication because they can 
reach uneducated population segments35. In Brazil, family 
healthcare is a model in which the population covered has 
a relationship of trust with the physicians, nurses and health 
agents at the healthcare unit and in home visits36. Thus, 
the MDA coverage supported by these professionals is an 
important model for tackling both LF and other diseases, 
such as hypertension and diabetes36. 
In the present study, one of the factors correlated 
with systematic noncompliance with MDA was fear of 
occurrence of adverse reactions. Studies conducted in 
India29,37-41 and Haiti42 have shown that fear of adverse 
reactions was the reason for systematic noncompliance 
that was most cited in the populations studied. In Kenya, 
adverse reactions experienced after drug consumption also 
contributed to low compliance43.
In the present survey, one of the main reasons for 
systematic noncompliance with MDA consisted of refusal 
of treatment because of not being ill: the interviewees 
stated that they did not have the disease and, hence, did not 
need treatment. Among the many reasons for systematic 
noncompliance with MDA, one important reason is that 
individuals do not see any morbidity caused by filariasis, 
in their immediate surroundings. Currently, because 
of worldwide efforts over the years, the frequency of 
individuals exhibiting chronic manifestations, such as 
elephantiasis and hydrocele, continues to decrease. Hence, 
filariasis is becoming less of a reason for societal concern33. 
In a study on the population of Jaboatão dos Guararapes, 
Medeiros et al.13 reported prevalence rates of 0.07% and 
0.78% for elephantiasis and hydrocele, respectively.
Another major reason for systematic noncompliance 
is that drug use is associated only with treatment and 
not with prophylaxis33,44,45. Approximately two-thirds of 
the infected population remain asymptomatic, and these 
individuals might not be aware of the benefits of treatment40. 
Albuquerque et al.46 observed a frequency of filariasis of 
6.2% in the population of Recife, Brazil. In a study on 
9,520 individuals in the municipality of Jaboatão dos 
Guararapes, Brazil, 323 were microfilaremic and 199 were 
asymptomatic (61.6 %)47. 
In the population investigated, two cases tested positive 
in the ICT and both of them were amicrofilaremic. In 
the future, these individuals would possibly become 
microfilaremic if they were not treated. Thus, they would 
have the capacity to participate in the local transmission 
cycle, given that the environmental conditions are favorable 
for C. quinquefasciatus to breed10,25. The impact of MDA 
is assessed through sentinel and spot-check sites in order 
to provide program managers with precise information 
on the evolution of infection, so that decisions can be 
made2. However, it should be noted that these ICT-positive 
individuals not characterized as a sentinel group and were 
resistant to MDA for four consecutive rounds. We suggest 
that the transmission assessment survey (TAS) or cross-
sectional surveys is included as a diagnostic tool with 
microfilaraemia and/ or antigenaemia (ICT or filariasis test 
srip) and/ and antibody in people who are systematically 
noncompliant with MDA. They will be used as technical 
validation indicators of lymphatic filariasis elimination as 
a public health problem in GPELF. 
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Pre-MDA educational campaigns need to emphasize the 
message that all individuals who live in endemic areas are 
at risk of infection and that even asymptomatic individuals 
may have become infected40. Campaigns on the importance 
of MDA need to aim the demystification of the risk of 
becoming ill through treatment with diethylcarbamazine. 
Furthermore, communities need to be made aware of 
the medication used as well as of the potential adverse 
reactions, and need to know that healthcare professionals 
are on standby and are qualified/ trained to treat them. The 
aim here is to gain the community’s trust and thus increase 
compliance with MDA. 
The present study had the limitation that no assessment 
was made on the impact of the population that was 
systematically noncompliant with MDA, regarding 
transmission of the infection. Nonetheless, the lack of 
previous investigations on this population in Brazil provided 
the justification for conducting this study, with the aim of 
contributing to educational campaigns and improving the 
strategies for drug distribution, and thus increasing the 
coverage of MDA.
The results of this research recommend the use of 
different PGELF strategies in Brazil according to the sex 
of the person who has systematic being noncompliant with 
MDA, for example, the men should receive home visits 
for distribution of the drug and women should receive 
information on the reasons for treatment compliance.
The success of GPELF depends on compliance with 
MDA and the risks of systematic noncompliance are 
significant and cannot be ignored. These include the 
possible appearance of resistance to drugs, the need 
for additional treatment rounds (with their respective 
costs) and “campaign fatigue” within the community 
and healthcare services48,49. Attention focusing on the 
population that is systematically noncompliant with 
MDA is crucial for ensuring adequate compliance with 
treatment and thereby optimizing actions and resources. 
The results from the present study revealed an evident 
need for surveillance of this population. Such observations 
will provide important information for achieving the goal 
of eliminating LF.
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